Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors (Q52297317)

28 April 2018

title

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors (English)

1 reference

https://api.crossref.org/works/10.1007/S10637-010-9541-0

17 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20857170

17 July 2024

author name string

Marcus Neubauer

3

1 reference

28 April 2018

Thomas Anderson

4

1 reference

28 April 2018

Mark Fleming

5

1 reference

28 April 2018

Yasir Nagarwala

6

1 reference

28 April 2018

Dawn Midwinter

8

1 reference

28 April 2018

Linda Vocila

9

1 reference

28 April 2018

Matthew D. Galsky

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20857170

17 July 2024

Daniel D. Von Hoff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20857170

17 July 2024

Janine M. Mahoney

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20857170

17 July 2024

Tal Z. Zaks

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20857170

17 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20857170

17 July 2024

publication date

22 September 2010

1 reference

28 April 2018

full work available at URL

https://link.springer.com/content/pdf/10.1007/s10637-010-9541-0.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S10637-010-9541-0

https://link.springer.com/article/10.1007/s10637-010-9541-0/fulltext.html

17 July 2024

1 reference

https://api.crossref.org/works/10.1007/S10637-010-9541-0

http://link.springer.com/content/pdf/10.1007/s10637-010-9541-0

17 July 2024

1 reference

https://api.crossref.org/works/10.1007/S10637-010-9541-0

Investigational New Drugs

17 July 2024

published in

1 reference

28 April 2018

volume

30

1 reference

28 April 2018

issue

2

1 reference

28 April 2018

page(s)

695-701

1 reference

28 April 2018

Rethinking clinical trials for cytostatic drugs

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9541-0

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

21 January 2018

1 reference

12 December 2020

A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma

1 reference

12 December 2020

Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics

1 reference

12 December 2020

HER-2/neu expression: a major prognostic factor in endometrial cancer

1 reference

12 December 2020

C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer

1 reference

12 December 2020

Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

1 reference

12 December 2020

Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

1 reference

12 December 2020

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

1 reference

12 December 2020

Identifiers

1 reference

28 April 2018

1 reference

28 April 2018